Grant: CIHR Fellowship
University of Toronto
$110,000.00
SweetPee: an ENU generated SGLT2 mouse mutant model of renal glucosuria
EF 2009-10
Résumé
The 21st century is marked by the pandemic of diabetes, both in the developed and developing countries. Diabetes causes microvascular complications including kidney failure, blindness, sensory deficits, poor wound healing, gangrene and limb amputations. In fact, diabetes is the leading cause of patients requiring dialysis. It also leads to life-threatening events such as heart attack and stroke. Diabetes is a devastating multi-organ disease that is costly on both personal and societal levels. The optimal control of diabetes remains a clinical challenge. It is imperative that we continue to strive for improving diabetes treatment and prevention of diabetic complications.
The primary objective of the current proposal is two fold:
1)To study the inhibition of glucose re-absorption in the kidneys as a novel treatment for diabetes using a new mouse model;
2)To interrogate the safety of blocking glucose re-absorption with this model.
We have generated a novel mouse model of glucosuria (sugar in urine). It contains a mutation in the gene known as SLC5a2 that encodes a protein SGLT2. SGLT2 is a sodium-glucose co-transporter which functions to reabsorb the majority (90%) of the glucose filtered through the kidneys. Affected mutants waste glucose in the urine. We induce diabetes in these mice and investigate if dysfunction of this protein leads to better blood glucose control and amelioration of end-organ damages including the kidneys.
Recently, active research has been conducted to target SGLT2 in the kidneys for treatment of diabetes. Individuals with the same mutation live a normal lifespan without developing hypoglycemia. We use our current mouse model to study the safety and efficacy of targeting this gene in the treatment of diabetes.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
206434
Name
Ly Joseph P
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
SweetPee: an ENU generated SGLT2 mouse mutant model of renal glucosuria
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$110,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Diabetes; Diabetic Nephropathy; Enu Mutagenesis; Forward Genetics; Glucose Metabolism; Glycemic Control; Molecular Biology; Renal Flow Dynamics; Renal Glucosuria; Sglt2
Abstract
The 21st century is marked by the pandemic of diabetes, both in the developed and developing countries. Diabetes causes microvascular complications including kidney failure, blindness, sensory deficits, poor wound healing, gangrene and limb amputations. In fact, diabetes is the leading cause of patients requiring dialysis. It also leads to life-threatening events such as heart attack and stroke. Diabetes is a devastating multi-organ disease that is costly on both personal and societal levels. The optimal control of diabetes remains a clinical challenge. It is imperative that we continue to strive for improving diabetes treatment and prevention of diabetic complications.
The primary objective of the current proposal is two fold:
1)To study the inhibition of glucose re-absorption in the kidneys as a novel treatment for diabetes using a new mouse model;
2)To interrogate the safety of blocking glucose re-absorption with this model.
We have generated a novel mouse model of glucosuria (sugar in urine). It contains a mutation in the gene known as SLC5a2 that encodes a protein SGLT2. SGLT2 is a sodium-glucose co-transporter which functions to reabsorb the majority (90%) of the glucose filtered through the kidneys. Affected mutants waste glucose in the urine. We induce diabetes in these mice and investigate if dysfunction of this protein leads to better blood glucose control and amelioration of end-organ damages including the kidneys.
Recently, active research has been conducted to target SGLT2 in the kidneys for treatment of diabetes. Individuals with the same mutation live a normal lifespan without developing hypoglycemia. We use our current mouse model to study the safety and efficacy of targeting this gene in the treatment of diabetes.
Competitiondate
201002
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Ly, Joseph P
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $110,000~ $0~